Route 92 Medical has announced the company’s 100th global issued patent for its innovative neurovascular intervention product portfolio, as per a press release. The company offers a range of solutions for neurovascular interventional procedures, including its FreeClimb catheter systems and Monopoint operating platform—both of which are powered by its Tenzing delivery catheter.
“Our FreeClimb and HiPoint catheters work as a system with our Tenzing delivery paradigm,” said Route 92 chief technology officer John Miller. “Collectively, these solutions work harmoniously as part of our Monopoint operating platform to enhance procedural efficiency and enable the delivery of large-bore and super-bore catheters without a microcatheter, and with reduced use of a guidewire. The ability of this technology to simplify stroke treatment is unique. This technology is designed to streamline the procedure, creating single-operator control over all elements, with the goal of reducing procedure time and cost while improving patient outcomes.”
“Route 92 has reinvented neurovascular intervention and will vigorously defend our intellectual property, which underlies our ability to continue to develop new solutions for arterial and venous access, and treatment, in the brain,” said Tony Chou, the company’s chief executive officer and founder. “In 2024, we plan to continue to build the evidence base to support the clinical adoption of our stroke solutions. We will also focus on growing our product portfolio and improving operational effectiveness to enable us to scale our business for commercial success.”
According to its recent company release, Route 92’s first step in “revolutionising” neurovascular intervention is focused on acute ischaemic stroke, and it will be launching a range of reperfusion systems that utilise innovative designs—including the Tenzing delivery catheter. Such products are intended to function “seamlessly” as a comprehensive system, enhancing the effectiveness of endovascular thrombectomy procedures.
Route 92 has a global intellectual property position with “strong protection” for its inventions in key markets, including the USA, Europe, and China. The company’s patent portfolio is “growing rapidly”, with a total of eight patents issued in 2023.
